Jordan Alana Ciuro, MD, breaks down key factors to consider when determining whether to treat mHSPC with a doublet or triplet regimen, including disease burden, patient fitness, toxicity, and accessibility. Dr. Ciuro reviews findings from CHAARTED, STAMPEDE, TITAN, ENZAMET, ARASENS, and PEACE-1, highlighting when ADT with an ARSI is sufficient and when adding chemotherapy (docetaxel) may improve survival. ...
mHSPC/mCSPC
Advertisement
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In 53.3% of cases, PSMA PET positively identified bone disease despite negative findings on bone scintigraphy.
Patients with mHSPC who are younger, have a high BMI, or have low-volume disease may benefit more from treatment with ARPIs.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
Advertisement
Roundtable Discussions
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Prostate Cancer Knowledge Hubs
Advertisement
Section Editor
Jordan Ciuro, MDAssistant Professor of Medicine & Medical Oncologist | Emory Winship Cancer Institute
Advertisement
Get the latest mHSPC research straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.